FibroScan® expert 630 by echosens

Next Generation FibroScan®

FibroScan® Expert 630
The complete non-invasive solution for advanced liver disease management

Powered by unique, patented and validated parameters: LSM by VCTE™, CAP™ and SSM by VCTE™ as part of an overall assessment of the liver.

NEW Guided VCTE™
The next generation VCTE™ technology

Intuitive features for faster examinations and simplified scanning[1]

- Two new indicators that allow for quick identification of the optimal measurement location
- AutoScan feature which triggers 10 valid measurements through a single click
- SmartExam features fully included: SmartDepth and Continuous CAP™

Stiffness indicator

CAP™ indicator

Enhance exam efficiency

- High-speed processing
- 19 inch touchscreen & washable touch keyboard
- Two probe connectors to easily switch between probes during exam
- For spleen examination: the M+ probe automatically adjusts to 100 Hz, adapts measurement depth, and adjusts the stiffness range

Ultrasound localization probe:
Time-saving technology for easily locating the spleen and liver in complex patients and patients with obesity.

Adapted to all patient morphologies

Probes S+, M+ and XL+

Unique capabilities of SSM by VCTE™

Management and risk stratification of patients with advanced chronic liver disease[2,3,4]

- **Assess and Monitor Portal Hypertension***
  SSM by VCTE™ helps to assess and monitor portal hypertension, the main driver of cirrhosis, in a quick and non-invasive way.
- **Helps to Assess the Presence of Esophageal Varices***
  SSM by VCTE™ can provide added value to help identify high-risk varices and prioritize endoscopies.
- **Determine Surgery***
  SSM by VCTE™ has the potential to triage patients in the general surgical population by assessing portal hypertension, a known risk factor, prior to surgery.

* SSM is a marker for non-invasive evaluation of spleen stiffness which has been used in a clinical setting to assess portal hypertension and for variceal surveillance.

Liver Health MANAGEMENT

Enhance your FibroScan® experience with the Liver Health Management platform

LHM platform is currently available in some countries. Contact us to find out if LHM platform is available in your country or when it will be launched.

What makes FibroScan® unique?

- A painless exam that can be performed in **less than 4 minutes** with immediate results at the point-of-care.[1]
- Can be performed by **any trained operator** (physician, nurse, or medical assistant).
- Standardized examination with exceptional precision and reproducibility that can be utilized in **99% of patients**.[5]
- An **ecosystem of solutions** developed by Echosens to support clinical decisions for physicians: Liver Health Management platform, Scores by Echosens[6,7], Interpretation Guide, myFibroScan, FibroScan® Gateway and educational support.

Renowned Publication Presence & Endorsement in Clinical Practice Guidelines

4,200+ peer-reviewed publications

180+ international guidelines

More than 4,200 peer-reviewed publications and 180 international guidelines advocate the use of FibroScan® as the reference non-invasive solution for liver fibrosis, cirrhosis, and steatosis assessment **across all etiologies of chronic liver disease (viral hepatitis, MASLD/MASH, alcoholic liver disease).**[4,8,9]

AASLD | ADA | AHA | APASL | EASL

AACE | AGA | AISF | Baveno VII | NICE Guidance

Examinations with FibroScan® can inform treatment decisions across the spectrum of disease



Interested in FibroScan® Expert 630 for your practice?
Contact us on echosens.com

LSM: Liver Stiffness Measurement / VCTE™: Vibration Controlled Transient Elastography / CAP™: Controlled Attenuation Parameter / SSM: Spleen Stiffness Measurement / MASLD: Metabolic dysfunction-associated steatotic liver disease (formerly known as NAFLD) / MASH: Metabolic dysfunction-associated steatohepatitis (formerly known as NASH) / LHM: Liver Health Management

References

1. Based on internal data. E431R020.1. **2.** Stefanescu H, *et al.* A novel spleen-dedicated stiffness measurement by FibroScanR improves the screening of high-risk oesophageal varices. Liver Int. 2020;40(1):175-185. doi:10.1111/liv.14228. **3.** Dajti, Elton *et al.* "A Combined Baveno VII and Spleen Stiffness Algorithm to Improve the Noninvasive Diagnosis of Clinically Significant Portal Hypertension in Patients With Compensated Advanced Chronic Liver Disease." The American journal of gastroenterology vol. 117,11 (2022): 1825-1833. doi:10.14309/ajg.0000000000001887. **4.** Baveno VII – R. de Franchis *et al.* Renewing consensus in portal hypertension. Journal of hepatology vol. 76,4 (2022): 959-974. doi:10.1016/j.jhep.2021.12.022. **5.** Myers, Robert P *et al.* "Feasibility and diagnostic performance of the FibroScan XL probe for liver stiffness measurement in overweight and obese patients." Hepatology (Baltimore, Md.) vol. 55,1 (2012): 199-208. doi:10.1002/hep.24624. **6.** Newsome, Philip N *et al.* "FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation study." The lancet. Gastroenterology & hepatology vol. 5,4 (2020): 362-373. doi:10.1016/S2468-1253(19)30383. **7.** Sanyal, Arun J *et al.* "Enhanced diagnosis of advanced fibrosis and cirrhosis in individuals with NAFLD using FibroScan-based Agile scores." Journal of hepatology vol. 78,2 (2023): 247-259. doi:10.1016/j.jhep.2022.10.034. **8.** European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu *et al.* "EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis - 2021 update." Journal of hepatology vol. 75,3 (2021): 659-689. **9.** Kanwal, Fasiha *et al.* "Clinical Care Pathway for the Risk Stratification and Management of Patients With Nonalcoholic Fatty Liver Disease." Gastroenterology vol. 161,5 (2021): 1657-1669.

One-pager FibroScan® Expert 630 – v2 ROW – 09/2024.